Treatment of neurogenic lower urinary tract symptoms: main contributions from 2018 and 2019
Purpose of review This review aims to update the studies involving the treatment of lower urinary tract symptoms (LUTS) in neurogenic patients, published in the last two years. Recent findings Treatment of neurogenic LUTS (NLUTS) patients with β3 adrenoreceptor agonists was investigated in real-life conditions. A randomized controlled trial compared the efficacy of antimuscarinics versus onabotulinum toxin A in neurogenic patients. The use of desmopressin to treat nocturia in multiple sclerosis patients is also reported. The long-term treatment with BontA efficacy, its discontinuation, and possible strategies to maintain patients on treatment were also evaluated. Sacral neuromodulation and tibial nerve stimulation are continuously being evaluated in neurogenic patients, especially in the last years. Summary The management of urinary tract infections and vesical lithiasis, two common complications in NLUTS patients, and the management of both these patients was assessed in clinical trials. A trial evaluating the use of the anti-Nogo-A antibody after a spinal cord injury to facilitate neuronal rewiring and prevent or improve NLUTS was reported for the first time.
Authors: Tünel M, Çakmak S, Tamam L, Demir T Abstract Normal pressure hydrocephalus (NPH), typically associated with the triad of gait disturbance, dementia and urinary incontinence, rarely presents with symptoms of mania, depression or psychosis and psychiatric disorders may complicate the diagnosis. Few cases of NPH and psychiatric disease comorbidity have been reported so far. In most of these cases, NPH was associated with depression and psychotic symptoms. Mania symptoms were also reported in a few cases those of which were associated with a history of bipolar disorder (BPD) or subthreshold BPD sym...
Authors: Iodice R, Ugga L, Aruta F, Iovino A, Ruggiero L Abstract Facioscapulohumeral muscular dystrophy 1 (FSHD1) is an autosomal dominant neuromuscular disorder, associated with reduction of tandemly arrayed repetitive DNA elements D4Z4 (DRA), at 4q35. Few cases, especially carriers of 1-3 DRA show a syndromic form. Anecdotally the association of FSHD with multiple sclerosis (MS) is reported. Herein we report a 33 years old Caucasian with a molecular diagnosis of FSHD1 with classical phenotype (clinical category A2) and concomitant white matter lesions suggestive of MS. White matter lesions in patients with FSHD ...
Conclusion: Our study provides convincing evidence that CSF sCD146 is a sensitive marker of BBB damage and neuroinflammation. Furthermore, sCD146 is actively involved in BBB dysfunction.
Conclusion: These results suggest that dNP2-LRR is a novel agent, which regulates effector T cell functions and could be a promising molecule for the treatment of CNS autoimmune diseases such as multiple sclerosis.
Publication date: July–August 2020Source: Journal of Minimally Invasive Gynecology, Volume 27, Issue 5Author(s): Laurentiu Pirtea, Oana Balint, Cristina Secoșan, Dorin Grigoraș, Razvan Ilina
Publication date: Available online 2 July 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Gustavo Saposnik, Javier Sotoca, Ángel P. Sempere, Antonio Candeliere-Merlicco, Paola Díaz-Abós, Philippe Tobler, María Terzaghi, Jorge Maurino
Publication date: Available online 2 July 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Heidi Øyen Flemmen, Cecilia Smith Simonsen, Pål Berg-Hansen, Stine Marit Moen, Hege Kersten, Kristian Heldal, Elisabeth Gulowsen Celius
Publication date: Available online 2 July 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): L. Lorefice, E. Carta, J. Frau, F. Contu, E. Casaglia, G. Coghe, M.A. Barracciu, E. Cocco, G. Fenu
Publication date: Available online 1 July 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Xiao Yang, Chenyang Zhang, Jun Zhang, Guisheng Chen, Li Zhao, Ping Yang, Huilu Li, Youming Long
Authors: Yilmaz V, Ulusoy C, Hajtovic S, Turkoglu R, Kurtuncu M, Tzartos J, Lazaridis K, Tuzun E Abstract Antigen-specific immune responses are crucially involved in both multiple sclerosis (MS) and myasthenia gravis (MG). Teriflunomide is an immunomodulatory agent approved for treatment of MS through inhibition of lymphocyte proliferation. MG associated with muscle-specific tyrosine kinase (MuSK) antibodies often manifests with a severe disease course, prompting development of effective treatment methods. To evaluate whether teriflunomide treatment may ameliorate MuSK-autoimmunity, experimental autoimmune MG (EAMG...